Aculys Overview
- Year Founded
-
2021
- Status
-
Acquired/Merged
- Employees
-
15
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$35M
Aculys General Information
Description
Operator of a clinical-stage biopharmaceutical company intended to eliminate drug lag/drug loss in Japan and is working to resolve social issues related to neurological and psychiatric diseases. The company creates drugs that are aimed at helping patients who are suffering from debilitating neurologic diseases and specializes in central nervous system treatment, enabling patients to improve their quality of life.
Contact Information
Website
www.aculys.com(Operating Subsidiary)
Corporate Office
- 2-14-4 Kita-Aoyama
- Minato-ku
- Tokyo
- Japan
Corporate Office
- 2-14-4 Kita-Aoyama
- Minato-ku
- Tokyo
- Japan
Aculys Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 15-Oct-2025 | $35M | Completed | Clinical Trials - Phase 3 | ||
| 4. Later Stage VC (Series C) | 11-Feb-2025 | Completed | Clinical Trials - Phase 3 | |||
| 3. Early Stage VC (Series B) | 22-Feb-2022 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series A) | 28-Oct-2021 | $61.3M | $64.5M | Completed | Startup | |
| 1. Seed Round | 28-Oct-2021 | $3.2M | $3.2M | Completed | Startup |
Aculys Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| C Preferred | ||||||||
| B Preferred | ||||||||
| A Preferred | 9,457,958 | $4.72 | $4.72 | 1x | $4.72 | 47.92% |
Aculys Comparisons
Industry
Financing
Details
Aculys Competitors (16)
One of Aculys’s 16 competitors is Neurentis, a Corporation company based in London, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Neurentis | Corporation | London, United Kingdom | ||||
| Citryll | Venture Capital-Backed | Oss, Netherlands | ||||
| Intracellular Therapies | Formerly VC-backed | Bedminster, NJ | ||||
| Cristal Therapeutics | Venture Capital-Backed | Maastricht, Netherlands | ||||
| TheraVida | Venture Capital-Backed | Chapel Hill, NC |
Aculys Signals
Aculys Former Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ANRI | Venture Capital | Minority | ||
| Catalys Pacific | Venture Capital | Minority | ||
| Global Founders Capital | Venture Capital | Minority | ||
| HBM Healthcare Investments | Venture Capital | Minority | ||
| HBM Partners | Venture Capital | Minority |
Aculys FAQs
-
When was Aculys founded?
Aculys was founded in 2021.
-
Where is Aculys headquartered?
Aculys is headquartered in Tokyo, Japan.
-
What is the size of Aculys?
Aculys has 15 total employees.
-
What industry is Aculys in?
Aculys’s primary industry is Drug Discovery.
-
Is Aculys a private or public company?
Aculys is a Private company.
-
What is the current valuation of Aculys?
The current valuation of Aculys is .
-
What is Aculys’s current revenue?
The current revenue for Aculys is .
-
How much funding has Aculys raised over time?
Aculys has raised $118M.
-
Who are Aculys’s investors?
ANRI, Catalys Pacific, Global Founders Capital, HBM Healthcare Investments, and HBM Partners are 5 of 14 investors who have invested in Aculys.
-
Who are Aculys’s competitors?
Neurentis, Citryll, Intracellular Therapies, Cristal Therapeutics, and TheraVida are some of the 16 competitors of Aculys.
-
When was Aculys acquired?
Aculys was acquired on 15-Oct-2025.
-
Who acquired Aculys?
Aculys was acquired by Viatris.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process